CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announced that the Company’s GMP manufacturer partner NCK A/S, received a Certificate of Analysis for its Active Pharma Ingredient, clearing it for use in the production of Berubicin.
October 1, 2020
· 4 min read